Immunogenicity of mAbs in non-human primates during nonclinical safety assessment

References

• Baldrick P. Safety evaluation of biological drugs: what are toxicology studies in primates telling us?. Regul Toxicol Pharmacol 2011; 59:227 - 36; http://dx.doi.org/10.1016/j.yrtph.2010.10.005; PMID: 20937341
   PubMed Web of Science ®Google Scholar
• Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 2005; 20:Suppl 6 vi3 - 9; http://dx.doi.org/10.1093/ndt/gfh1092; PMID: 15958824
   PubMedGoogle Scholar
• Schellekens H.. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther. 2002; 24:1720 - 40 discussion 19
   Google Scholar
• Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant 2006; 21:Suppl 5 v9 - 12; http://dx.doi.org/10.1093/ndt/gfl476; PMID: 16959792
   PubMed Web of Science ®Google Scholar
• Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 2009; 21:211 - 5; http://dx.doi.org/10.1097/BOR.0b013e328329ed8b; PMID: 19399992
   PubMed Web of Science ®Google Scholar
• Koren E, De Groot AS, Jawa V, Beck KD, Boone T, Rivera D, et al. Clinical validation of the “in silico” prediction of immunogenicity of a human recombinant therapeutic protein. Clin Immunol 2007; 124:26 - 32; http://dx.doi.org/10.1016/j.clim.2007.03.544; PMID: 17490912
   PubMed Web of Science ®Google Scholar
• De Groot AS, Knopp PM, Martin W. De-immunization of therapeutic proteins by T-cell epitope modification. Dev Biol (Basel) 2005; 122:171 - 94; PMID: 16375261
   PubMedGoogle Scholar
• Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2010; 2:256 - 65; http://dx.doi.org/10.4161/mabs.2.3.11641; PMID: 20400861
   PubMed Web of Science ®Google Scholar
• Gaitonde P, Balu-Iyer SV. In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting. Methods Mol Biol 2011; 716:267 - 80; http://dx.doi.org/10.1007/978-1-61779-012-6_16; PMID: 21318912
   PubMedGoogle Scholar
• Brennan FR, Morton LD, Spindeldreher S, Kiessling A, Allenspach R, Hey A, et al. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. MAbs 2010; 2:233 - 55; http://dx.doi.org/10.4161/mabs.2.3.11782; PMID: 20421713
   PubMed Web of Science ®Google Scholar
• Bugelski PJ, Treacy G. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr Opin Mol Ther 2004; 6:10 - 6; PMID: 15011776
   PubMed Web of Science ®Google Scholar
• Descotes J. Immunotoxicity of monoclonal antibodies. MAbs 2009; 1:104 - 11; http://dx.doi.org/10.4161/mabs.1.2.7909; PMID: 20061816
   PubMed Web of Science ®Google Scholar
• International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Preclinical safety evaluation of biotechnology derived pharmaceuticals S6(R1). (online) 2011.
   Google Scholar
• Committee for medicinal products for human use. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. 2008.
   Google Scholar
• Brinks V, Jiskoot W, Schellekens H. Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res 2011; 28:2379 - 85; http://dx.doi.org/10.1007/s11095-011-0523-5; PMID: 21744171
   PubMed Web of Science ®Google Scholar
• Wierda D, Smith HW, Zwickl CM. Immunogenicity of biopharmaceuticals in laboratory animals. Toxicology 2001; 158:71 - 4; http://dx.doi.org/10.1016/S0300-483X(00)00410-8; PMID: 11164995
   PubMed Web of Science ®Google Scholar
• Ponce R, Abad L, Amaravadi L, Gelzleichter T, Gore E, Green J, et al. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul Toxicol Pharmacol 2009; 54:164 - 82; http://dx.doi.org/10.1016/j.yrtph.2009.03.012; PMID: 19345250
   PubMed Web of Science ®Google Scholar
• Swanson SJ, Bussiere J. Immunogenicity assessment in non-clinical studies. Curr Opin Microbiol 2012; 15:337 - 47; http://dx.doi.org/10.1016/j.mib.2012.05.015; PMID: 22770538
   PubMed Web of Science ®Google Scholar
• Gorovits B. Antidrug antibody assay validation: industry survey results. AAPS J 2009; 11:133 - 8; http://dx.doi.org/10.1208/s12248-009-9091-6; PMID: 19255857
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305:1460 - 8; http://dx.doi.org/10.1001/jama.2011.406; PMID: 21486979
   PubMed Web of Science ®Google Scholar
• de Vries MK, Wolbink GJ, Stapel SO, de Vrieze H, van Denderen JC, Dijkmans BA, et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 2007; 66:1252 - 4; http://dx.doi.org/10.1136/ard.2007.072397; PMID: 17472991
   PubMed Web of Science ®Google Scholar
• Isaacs JD, Manna VK, Rapson N, Bulpitt KJ, Hazleman BL, Matteson EL, et al. CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study. Br J Rheumatol 1996; 35:231 - 40; http://dx.doi.org/10.1093/rheumatology/35.3.231; PMID: 8620297
   PubMedGoogle Scholar
• Schellekens H. The immunogenicity of therapeutic proteins. Discov Med 2010; 9:560 - 4; PMID: 20587346
   PubMed Web of Science ®Google Scholar
• Curtis BR, Swyers J, Divgi A, McFarland JG, Aster RH. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 2002; 99:2054 - 9; http://dx.doi.org/10.1182/blood.V99.6.2054; PMID: 11877279
   PubMed Web of Science ®Google Scholar
• Getts DR, Getts MT, McCarthy DP, Chastain EM, Miller SD. Have we overestimated the benefit of human(ized) antibodies?. MAbs 2010; 2:682 - 94; http://dx.doi.org/10.4161/mabs.2.6.13601; PMID: 20935511
   PubMed Web of Science ®Google Scholar
• Clark M. Antibody humanization: a case of the ‘Emperor’s new clothes’?. Immunol Today 2000; 21:397 - 402; http://dx.doi.org/10.1016/S0167-5699(00)01680-7; PMID: 10916143
   PubMedGoogle Scholar
• Büttel IC, Chamberlain P, Chowers Y, Ehmann F, Greinacher A, Jefferis R, et al. Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals 2011; 39:100 - 9; http://dx.doi.org/10.1016/j.biologicals.2011.01.006; PMID: 21353596
   PubMed Web of Science ®Google Scholar
• Koren E, Zuckerman LA, Mire-Sluis AR. Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction. Curr Pharm Biotechnol 2002; 3:349 - 60; http://dx.doi.org/10.2174/1389201023378175; PMID: 12463417
   PubMedGoogle Scholar
• Thullier P, Chahboun S, Pelat T. A comparison of human and macaque (Macaca mulatta) immunoglobulin germline V regions and its implications for antibody engineering. MAbs 2010; 2:528 - 38; http://dx.doi.org/10.4161/mabs.2.5.12545; PMID: 20562531
   PubMed Web of Science ®Google Scholar
• Shankar G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol 2007; 25:555 - 61; http://dx.doi.org/10.1038/nbt1303; PMID: 17483842
   PubMed Web of Science ®Google Scholar
• Wadhwa M, Thorpe R. Strategies and assays for the assessment of unwanted immunogenicity. J Immunotoxicol 2006; 3:115 - 21; http://dx.doi.org/10.1080/15476910600845534; PMID: 18958691
   PubMedGoogle Scholar
• Chapman K, Pullen N, Coney L, Dempster M, Andrews L, Bajramovic J, et al. Preclinical development of monoclonal antibodies: considerations for the use of non-human primates. MAbs 2009; 1:505 - 16; http://dx.doi.org/10.4161/mabs.1.5.9676; PMID: 20065651
   PubMed Web of Science ®Google Scholar
• Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods 2005; 36:3 - 10; http://dx.doi.org/10.1016/j.ymeth.2005.01.001; PMID: 15848070
   PubMed Web of Science ®Google Scholar